Stay updated on Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial
Sign up to get notified when there's something new on the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page.

Latest updates to the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page
- Check2 days agoChange DetectedRevision: v3.3.4 deployed; no visible updates to study details, eligibility criteria, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoChange DetectedAdded Durban site (South Africa, 4091) and updated the Lancet HIV 2021 publication entry, replacing the previous Durban site (4001). Updated the page's Last Update Posted dates to December 2025.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedExplicit study locations have been added, spanning multiple US states and Canadian provinces. Older location headings and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.8%

- Check37 days agoChange DetectedPublications section updated: added a 2025 AIDS article by D'Amico et al. and removed the 2025 July online-ahead-of-print entry for the same study. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check52 days agoChange DetectedThe publications are automatically filled in from PubMed, and Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check59 days agoChange DetectedThe page no longer shows the government funding notice about operating status. Core study details, design, endpoints, and locations are unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page.